

To,

Date: 12/11/2018

- 1) BSE Limited  
P.J. Towers, Dalal Street,  
Mumbai – 400 001
- 2) Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4<sup>th</sup> floor, Plot No C 62, Opp. Trident Hotel,  
Bandra Kurla Complex, Bandra (E), Mumbai – 400 098
- 3) Ahmedabad Stock Exchange Limited  
Kamdheni Complex, Opp. Sahajanand College,  
Panjara Pole, Ambawadi, Ahmedabad – 380 015

Sub: Outcome of Board Meeting under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Company's Letter dated Wednesday, 31<sup>st</sup> October, 2018

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, 12<sup>th</sup> November, 2018 at Registered Office, have considered and approved inter-alia, the following:

1. Standalone Un-Audited Financial Results for Quarter II and Half Year Ended 30<sup>th</sup> September, 2018
2. Statement of Assets and Liabilities for Half Year Ended 30<sup>th</sup> September, 2018
3. Limited Review Report for Quarter II and Half Year Ended 30<sup>th</sup> September, 2018 issued by M/s. MSKA & Associates, Statutory Auditors of the Company.

The meeting commenced at 3.00 PM and concluded at 4.00 PM.

Request you take the same on records.

Thanking you.

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju  
Executive Chairman (DIN 00874650)



Encl: as above

## Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

**Regd.Off** : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India  
**Corp Off** : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008.TS. India  
**CIN No.** : L85110TG1996PLC099198  
**Contact No.:** 040 - 2970 3333, +91 9030057370

Email : [info@drhsl.com](mailto:info@drhsl.com), [pcproductsindia@gmail.com](mailto:pcproductsindia@gmail.com)  
Website : [www.drhsl.com](http://www.drhsl.com)

PART-I		Rs in Lakhs					
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER II AND HALF YEAR ENDED 30TH SEPTEMBER, 2018							
S.No	Particulars	QUARTER ENDED			Half Year ended		Year ended 31
		3 Months ended 30-09-2018	Corresponding 3 months ended in previous year 30-09-2017	Preceding 3 months ended 30-06-2018	Half year ended 30-09-2018	Half year ended 30-09-2017	03-2018
		UnAudited	UnAudited	UnAudited	UnAudited	UnAudited	Audited
I	Revenue from Operations	52.92	14.95	30.46	83.38	17.50	61.67
II	Other income	-	-	-	-	-	-
III	Total Revenue (III)	52.92	14.95	30.46	83.38	17.50	61.67
IV	Expenses						
	Cost of Material Consumed	4.96	0.56	3.11	8.07	0.56	6.41
	Purchase of Stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-	-	-
	Employee benefits expense	31.29	17.82	34.37	65.66	40.01	87.42
	Finance Costs	-	-	-	-	-	-
	Depreciation and Amortisation expense	0.09	-	0.09	0.18	-	0.23
	Professional Charges	14.43	-	10.81	25.24	-	-
	Other Expenses	60.71	6.28	44.85	105.56	17.45	69.77
	Total Expenses	111.48	24.66	93.23	204.71	58.02	163.82
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(58.56)	(9.71)	(62.77)	(121.33)	(40.52)	(102.15)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(58.56)	(9.71)	(62.77)	(121.33)	(40.52)	(102.15)
VIII	Tax Expense:	-	-	-	-	-	-
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(58.56)	(9.71)	(62.77)	(121.33)	(40.52)	(102.15)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(58.56)	(9.71)	(62.77)	(121.33)	(40.52)	(102.15)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(58.56)	(9.71)	(62.77)	(121.33)	(40.52)	(102.15)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.49)	(0.09)	(0.53)	(1.02)	(0.40)	(0.96)
	2) Diluted	(0.40)	(0.09)	(0.45)	(0.84)	(0.40)	(0.74)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.49)	(0.09)	(0.53)	(0.98)	(0.40)	(0.96)
	2) Diluted	(0.40)	(0.09)	(0.45)	(0.81)	(0.40)	(0.74)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,221.37	1025.87	1,221.37	1,221.37	1025.87	1175.87
XX	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	(142.23)	(190.07)	(142.23)	(142.23)	(190.07)	(142.23)

79



## Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

**Notes:**


1. The Unaudited Standalone financial results for the Quarter II and period ended 30, September 2018 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on November 12, 2018. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).
2. The Unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (IND AS) 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India ("SEBI") and Regulation 33 of SEBI (LODR) Regulations, 2015 and SEBI Circular dated 05th July, 2016.
3. Adoption of Ind AS 115 - Revenue from contracts with customers  
Effective April 1, 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers" using the cumulative catch-up transition method which is applied to contracts that were not completed as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The effect on adoption of Ind AS 115 was insignificant on the financial statements.
4. The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
5. The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
6. The results are also available on the website of the Company www.drhsl.com

Place : Hyderabad  
Date : 12/11/2018

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju  
Executive Chairman (DIN 00874650)



## Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd.Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India  
Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008.TS. India  
CIN No. : L85110TG1996PLC099198  
Contact No.: 040 - 2970 3333, +91 9030057370  
Email : info@drhsl.com, pproductsindia@gmail.com  
Website : www.drhsl.com

**Statement of Assets and Liabilities**

Particulars	(INR. in Lakhs )	
	Half Year Ended 30-09-18 Unaudited	Year Ended 31-03-18 Audited
<b>ASSETS</b>		
<b>Non Current Assets</b>		
Property, Plant and Equipments	3.43	1.99
Capital Work In Progress		
Investment Prpoerty		
Goodwill		
Other Intangible Assets		
Intangible Assets under development	153.03	91.66
Biological assets other than bearer plants		
Financial Assets:		
Investments	487.06	487.06
Trade Receivables		
Loans		
Others		
Deferred Tax Assets (net)		
Other Non Current Assets		
<b>Total Non Current Assets</b>	<b>643.53</b>	<b>580.71</b>
<b>Current Assets</b>		
Inventories	14.80	9.52
Financial Assets		
Investments		
Trade Receivables	217.68	287.4
Cash and Cash Equivalents	1.09	33.23
Bank balances other than above	5.86	
Loans	96.74	70
Others		
Current Tax Assets (net)		
Other Current Assets	300.22	241.85
<b>Total Current Assets</b>	<b>636.38</b>	<b>642.00</b>
<b>Total Assets</b>	<b>1,279.91</b>	<b>1,222.71</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	1,221.37	1,175.87
Other Equity		
Reserves & Surplus	(218.05)	(142.23)
Share warrants	129.75	152.50
<b>Total - Equity</b>	<b>1,133.07</b>	<b>1,186.14</b>




## Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

**Regd.Off** : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India  
**Corp Off** : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008.TS. India  
**CIN No.** : L85110TG1996PLC099198 Email : info@drhsl.com, pcproductsindia@gmail.com  
**Contact No.:** 040 - 2970 3333, +91 9030057370 Website : www.drhsl.com

<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
Financial Liabilities		
Borrowings	63.00	-
Trade Payables		
Other Financial Liabilities		
Provisions		
Deferred Tax Liabilities (net)		
Other Non Current Liabilities		
<b>Total Non Current Liabilities</b>	<b>63.00</b>	<b>-</b>
<b>Current Liabilities</b>		
Financial Liabilities		
Borrowings		
Trade Payables	23.44	6.21
Other Financial Liabilities		
Other Current Liabilities		24.11
Provisions	60.41	6.25
Current Tax Liabilities (net)		
<b>Total Current Liabilities</b>	<b>83.84</b>	<b>36.57</b>
<b>Total - Equity and Liabilities</b>	<b>1,279.91</b>	<b>1,222.71</b>

Place : Hyderabad  
Date : 12/11/2018

For DR HABEEBULLAH LIFE SCIENCES LIMF




**K. Krishnam Raju**  
Executive Chairman (DIN 00874650)

## Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)



**Regd.Off** : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad - 500048. TS.India  
**Corp Off** : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad - 500008.TS. India  
**CIN No.** : L85110TG1996PLC099198      Email : info@drhlsl.com, pcproductsindia@gmail.com  
**Contact No.:** 040 - 2970 3333, +91 9030057370      Website : www.drhlsl.com

**Limited Review Report****Review Report to  
The Board of Directors  
DR HABEEBULLAH LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results for the quarter ended 30<sup>th</sup> September, 2018 and the year to-date results for the period 1<sup>st</sup> April 2018 to 30<sup>th</sup> September, 2018 and financial position as on 30<sup>th</sup> September, 2018 ('the Statement') of DR HABEEBULLAH LIFE SCIENCES LIMITED ('the Company'), being submitted by the Company pursuant to the requirements of Regulation 33 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and Regulation 52 as modified by Circular No. CIR/IMD/DF1/69/2016 dated August 10, 2016 read with Regulation 63(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).  
This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results and financial position which are prepared in accordance with Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For MSKA & Associates (Formerly known as MZSK & Associates)**  
Chartered Accountants

ICAI Firm Registration No. 03047W

Ananthakrishnan G

Partner

Membership No.:205226

Place: Hyderabad

Date: 12<sup>th</sup> November, 2018



